Postmortem evidence of cerebral inflammation in schizophrenia: A systematic review

Molecular Psychiatry

Volumn 21, Issue 8, 2016, Pages 1009-1026

  Trepanier M O ^a   Hopperton, K E ^a   Mizrahi, R ^a,b,c   Mechawar, N ^d,e   Bazinet, R P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; BETA INTERFERON; BIOLOGICAL MARKER; CALGRANULIN; CD11B ANTIGEN; CD68 ANTIGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOKINE; CYTOSOLIC PHOSPHOLIPASE A2; GAMMA INTERFERON; GLIAL FIBRILLARY ACIDIC PROTEIN; HLA A ANTIGEN; HLA B ANTIGEN; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; HLA DRB3 ANTIGEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN SYNTHASE; QUINOLINIC ACID; SUBSTANCE P; TUMOR NECROSIS FACTOR ALPHA;

ASTROCYTE; AUTOPSY; BRAIN REGION; CAUSE OF DEATH; CELL DENSITY; CELL DIFFERENTIATION; EMBASE; ENCEPHALITIS; GLIA CELL; HUMAN; MACROGLIA; MEDLINE; MICROGLIA; PRIORITY JOURNAL; PSYCINFO; REVIEW; SCHIZOPHRENIA; SUICIDE; BRAIN; FEMALE; GLIA; IMMUNOMODULATION; INFLAMMATION; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ASTROCYTES; AUTOPSY; BRAIN; CYTOKINES; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; INFLAMMATION; MALE; MICROGLIA; NEUROGLIA; NEUROIMMUNOMODULATION; SCHIZOPHRENIA;

EID: 84976286519     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2016.90     Document Type: Review

References (177)

1. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, just the facts what we know in 2008. 2. Epidemiology and etiology. Schizophr Res 2008; 102: 1-18.
2. van Os J, Kapur S. Schizophrenia. Lancet 2009; 374: 635-645.
3. Insel TR. Rethinking schizophrenia. Nature 2010; 468: 187-193.
4. Roussos P, Haroutunian V. Schizophrenia: susceptibility genes and oligodendroglial and myelin related abnormalities. Front Cell Neurosci 2014; 8: 5.
5. Karoutzou G, Emrich HM, Dietrich DE. The myelin-pathogenesis puzzle in schizophrenia: a literature review. Mol Psychiatry 2008; 13: 245-260.
6. Stephan KE, Friston KJ, Frith CD. Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophr Bull 2009; 35: 509-527.
7. Abi-Dargham A. Schizophrenia: overview and dopamine dysfunction. J Clin Psychiatry 2014; 75: e31.
8. Leza JC, Garcia-Bueno B, Bioque M, Arango C, Parellada M, Do K, et al. Inflammation in schizophrenia: a question of balance. Neurosci Biobehav Rev 2015; 55: 612-626.
9. Najjar S, Pearlman DM, Alper K, Najjar A, Devinsky O. Neuroinflammation and psychiatric illness. J Neuroinflammation 2013; 10: 43.
10. Reus GZ, Fries GR, Stertz L, Badawy M, Passos IC, Barichello T, et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 2015; 300: 141-154.
11. Muller N, Weidinger E, Leitner B, Schwarz MJ. The role of inflammation in schizophrenia. Front Neurosci 2015; 9: 372.
12. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. Immunol Rev 2006; 213: 48-65.
13. Cherry JD, Olschowka JA, OBanion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation 2014; 11: 98.
14. Rapoport SI. Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade. ACS Chem Neurosci 2014; 5: 459-467.
15. van Neerven S, Nemes A, Imholz P, Regen T, Denecke B, Johann S, et al. Inflammatory cytokine release of astrocytes in vitro is reduced by all-Trans retinoic acid. J Neuroimmunol 2010; 229: 169-179.
16. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimers disease. Lancet Neurol 2015; 14: 388-405.
17. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008; 63: 801-808.
18. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-Analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011; 70: 663-671.
19. Bamne M, Wood J, Chowdari K, Watson AM, Celik C, Mansour H, et al. Evaluation of HLA polymorphisms in relation to schizophrenia risk and infectious exposure. Schizophr Bull 2012; 38: 1149-1154.
20. Yue WH, Wang HF, Sun LD, Tang FL, Liu ZH, Zhang HX, et al. Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. Nat Genet 2011; 43: 1228-1231.
21. Pasternak O, Kubicki M, Shenton ME. In vivo imaging of neuroinflammation in schizophrenia. Schizophr Res 2015; 41: 85-93.
22. van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E, et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 2008; 64: 820-822.
23. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 2009; 50: 1801-1807.
24. Bloomfield PS, Selvaraj S, Veronese M, Rizzo G, Bertoldo A, Owen DR, et al. Microglial activity in people at ultra high risk of psychosis and in schizophrenia: an [(11)C]PBR28 PET brain imaging study. Am J Psychiatry 2016; 173: 44-52.
25. Kenk M, Selvanathan T, Rao N, Suridjan I, Rusjan P, Remington G, et al. Imaging neuroinflammation in gray and white matter in schizophrenia: an in vivo PET study with [18 F]-FEPPA. Schizophr Bull 2015; 41: 85-93.
26. Takano A, Arakawa R, Ito H, Tateno A, Takahashi H, Matsumoto R, et al. Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. Int J Neuropsychopharmacol 2010; 13: 943-950.
27. Muller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002; 159: 1029-1034.
28. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 2007; 90: 179-185.
29. Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010; 71: 520-527.
30. Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry 2005; 57: 1594-1596.
31. Nitta M, Kishimoto T, Muller N, Weiser M, Davidson M, Kane JM, et al. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-Analytic investigation of randomized controlled trials. Schizophr Bull 2013; 39: 1230-1241.
32. Trepanier MO, Hopperton KE, Orr SK, Bazinet RP. N-3 polyunsaturated fatty acids in animal models with neuroinflammation: an update. Eur J Pharmacol 2016; e-pub ahead of print
33. Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?. Br J Clin Pharmacol 2013; 75: 645-662.
34. Emsley R, Chiliza B, Asmal L, du Plessis S, Phahladira L, van Niekerk E, et al. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. Schizophr Res 2014; 158: 230-235.
35. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67: 146-154.
36. Buntinx M, Moreels M, Vandenabeele F, Lambrichts I, Raus J, Steels P, et al. Cytokine-induced cell death in human oligodendroglial cell lines: I. Synergistic effects of IFN-gamma and TNF-Alpha on apoptosis. J Neurosci Res 2004; 76: 834-845.
37. Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF-Alpha. Nature 2006; 440: 1054-1059.
38. Felger JC, Miller AH. Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front Neuroendocrinol 2012; 33: 315-327.
39. Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003; 302: 1760-1765.
40. Downen M, Amaral TD, Hua LL, Zhao ML, Lee SC. Neuronal death in cytokineactivated primary human brain cell culture: role of tumor necrosis factor-Alpha. Glia 1999; 28: 114-127.
41. Najjar S, Pearlman DM. Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophr Res 2015; 161: 102-112.
42. Tooyama I, Kimura H, Akiyama H, McGeer PL. Reactive microglia express class I and class II major histocompatibility complex antigens in Alzheimers disease. Brain Res 1990; 523: 273-280.
43. Roberts GW, Colter N, Lofthouse R, Bogerts B, Zech M, Crow TJ. Gliosis in schizophrenia: a survey. Biol Psychiatry 1986; 21: 1043-1050.
44. Roberts GW, Colter N, Lofthouse R, Johnstone EC, Crow TJ. Is there gliosis in schizophrenia?. Investigation of the temporal lobe. Biol Psychiatry 1987; 22: 1459-1468.
45. Arnold SE, Franz BR, Trojanowski JQ, Moberg PJ, Gur RE. Glial fibrillary acidic protein-immunoreactive astrocytosis in elderly patients with schizophrenia and dementia. Acta Neuropathol 1996; 91: 269-277.
46. Arnold SE, Trojanowski JQ, Gur RE, Blackwell P, Han LY, Choi C. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Arch Gen Psychiatry 1998; 55: 225-232.
47. Pantazopoulos H, Woo TUW, Lim MP, Lange N, Berretta S. Extracellular matrixglial abnormalities in the amygdala and entorhinal cortex of subjects diagnosed with schizophrenia. Arch Gen Psychiatry 2010; 67: 155-166.
48. Altshuler LL, Abulseoud OA, Foland-Ross L, Bartzokis G, Chang S, Mintz J, et al. Amygdala astrocyte reduction in subjects with major depressive disorder but not bipolar disorder. Bipolar Disord 2010; 12: 541-549.
49. Falkai P, Honer WG, David S, Bogerts B, Majtenyi C, Bayer TA. No evidence for astrogliosis in brains of schizophrenic patients. A post-mortem study. Neuropathol Appl Neurobiol 1999; 25: 48-53.
50. Falke E, Han LY, Arnold SE. Absence of neurodegeneration in the thalamus and caudate of elderly patients with schizophrenia. Psychiatry Res 2000; 93: 103-110.
51. Stevens CD, Altshuler LL, Bogerts B, Falkai P. Quantitative study of gliosis in schizophrenia and Huntingtons chorea. Biol Psychiatry 1988; 24: 697-700.
52. Williams MR, Marsh R, Macdonald CD, Jain J, Pearce RK, Hirsch SR, et al. Neuropathological changes in the nucleus basalis in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2013; 263: 485-495.
53. Radewicz K, Garey LJ, Gentleman SM, Reynolds R. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J Neuropathol Exp Neurol 2000; 59: 137-150.
54. Damadzic R, Bigelow LB, Krimer LS, Goldenson DA, Saunders RC, Kleinman JE, et al. A quantitative immunohistochemical study of astrocytes in the entorhinal cortex in schizophrenia, bipolar disorder and major depression: absence of significant astrocytosis. [References]. Brain Res Bull 2001; 55: 611-618.
55. Hercher C, Chopra V, Beasley CL. Evidence for morphological alterations in prefrontal white matter glia in schizophrenia and bipolar disorder. J Psychiatry Neurosci 2014; 39: 376-385.
56. Webster MJ, Knable MB, Johnston-Wilson N, Nagata K, Inagaki M, Yolken RH. Immunohistochemical localization of phosphorylated glial fibrillary acidic protein in the prefrontal cortex and hippocampus from patients with schizophrenia, bipolar disorder, and depression. Brain Behav Immun 2001; 15: 388-400.
57. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003; 362: 798-805.
58. Katsel P, Byne W, Roussos P, Tan W, Siever L, Haroutunian V. Astrocyte and glutamate markers in the superficial, deep, and white matter layers of the anterior cingulate gyrus in schizophrenia. Neuropsychopharmacology 2011; 36: 1171-1177.
59. Beasley CL, Dwork AJ, Rosoklija G, Mann JJ, Mancevski B, Jakovski Z, et al. Metabolic abnormalities in fronto-striatal-Thalamic white matter tracts in schizophrenia. Schizophr Res 2009; 109: 159-166.
60. Fatemi SH, Laurence JA, Araghi-Niknam M, Stary JM, Schulz SC, Lee S, et al. Glial fibrillary acidic protein is reduced in cerebellum of subjects with major depression, but not schizophrenia. Schizophr Res 2004; 69: 317-323.
61. Karson CN, Casanova MF, Kleinman JE, Griffin WST. Choline acetyltransferase in schizophrenia. Am J Psychiatry 1993; 150: 454-459.
62. Dean B, Gray L, Scarr E. Regionally specific changes in levels of cortical S100beta in bipolar 1 disorder but not schizophrenia. Aust N Z J Psychiatry 2006; 40: 217-224.
63. Karson CN, Mrak RE, Schluterman KO, Sturner WQ, Sheng JG, Griffin WS. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: a possible neurochemical basis for hypofrontality. Mol Psychiatry 1999; 4: 39-45.
64. Perrone-Bizzozero NI, Sower AC, Bird ED, Benowitz LI, Ivins KJ, Neve RL. Levels of the growth-Associated protein GAP-43 are selectively increased in association cortices in schizophrenia. Proc Natl Acad Sci USA 1996; 93: 14182-14187.
65. Feresten AH, Barakauskas V, Ypsilanti A, Barr AM, Beasley CL. Increased expression of glial fibrillary acidic protein in prefrontal cortex in psychotic illness. Schizophr Res 2013; 150: 252-257.
66. Steffek AE, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH. Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia. Schizophr Res 2008; 103: 71-82.
67. Williams MR, Hampton T, Pearce RK, Hirsch SR, Ansorge O, Thom M, et al. Astrocyte decrease in the subgenual cingulate and callosal genu in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2013; 263: 41-52.
68. Williams M, Pearce RK, Hirsch SR, Ansorge O, Thom M, Maier M. Fibrillary astrocytes are decreased in the subgenual cingulate in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2014; 264: 357-362.
69. Williams MR, Galvin K, OSullivan B, MacDonald CD, Ching EW, Turkheimer F, et al. Neuropathological changes in the substantia nigra in schizophrenia but not depression. Eur Arch Psychiatry Clin Neurosci 2014; 264: 285-296.
70. Rajkowska G, Miguel-Hidalgo JJ, Makkos Z, Meltzer H, Overholser J, Stockmeier C. Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. Schizophr Res 2002; 57: 127-138.
71. Toro CT, Hallak JE, Dunham JS, Deakin JF. Glial fibrillary acidic protein and glutamine synthetase in subregions of prefrontal cortex in schizophrenia and mood disorder. Neurosci Lett 2006; 404: 276-281.
72. Markova E, Markov I, Revishchin A, Okhotin V, Sulimov G. 3-D Golgi and image analysis of the olfactory tubercle in schizophrenia. Anal Quant Cytol Histol 2000; 22: 178-182.
73. Rao JS, Kim HW, Harry GJ, Rapoport SI, Reese EA. Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients. Schizophr Res 2013; 147: 24-31.
74. Barley K, Dracheva S, Byne W. Subcortical oligodendrocyte- And astrocyteassociated gene expression in subjects with schizophrenia, major depression and bipolar disorder. Schizophr Res 2009; 112: 54-64.
75. Catts VS, Wong J, Fillman SG, Fung SJ, Shannon Weickert C. Increased expression of astrocyte markers in schizophrenia: association with neuroinflammation. Aust N Z J Psychiatry 2014; 48: 722-734.
76. Webster MJ, OGrady J, Kleinman JE, Weickert CS. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 2005; 133: 453-461.
77. Hwang Y, Kim J, Shin JY, Kim JII, Seo JS, Webster MJ, et al. Gene expression profiling by mRNA sequencing reveals increased expression of immune/.inflammation-related genes in the hippocampus of individuals with schizophrenia. Transl Psychiatry 2013; 3: 1-9.
78. Steiner J, Schmitt A, Schroeter ML, Bogerts B, Falkai P, Turck CW, et al. S100B is downregulated in the nuclear proteome of schizophrenia corpus callosum. Eur Arch Psychiatry Clin Neurosci 2014; 264: 311-316.
79. Steiner J, Bernstein HG, Bielau H, Farkas N, Winter J, Dobrowolny H, et al. S100Bimmunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study. J Psychiatr Res 2008; 42: 868-876.
80. Casanova MF, Stevens JR, Kleinman JE. Astrocytosis in the molecular layer of the dentate gyrus: a study in Alzheimers disease and schizophrenia. Psychiatry Res 1990; 35: 149-166.
81. Schmitt A, Steyskal C, Bernstein HG, Schneider-Axmann T, Parlapani E, Schaeffer EL, et al. Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathol 2009; 117: 395-407.
82. Pakkenberg B. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch Gen Psychiatry 1990; 47: 1023-1028.
83. Kolomeets NS, Uranova N. Ultrastructural abnormalities of astrocytes in the hippocampus in schizophrenia and duration of illness: a postortem morphometric study. World J Biol Psychiatry 2010; 11: 282-292.
84. Uranova NA, Zimina IS, Vikhreva OV, Krukov NO, Rachmanova VI, Orlovskaya DD. Ultrastructural damage of capillaries in the neocortex in schizophrenia. World J Biol Psychiatry 2010; 11: 567-578.
85. Bayer TA, Buslei R, Havas L, Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett 1999; 271: 126-128.
86. Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T, et al. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 2013; 18: 206-214.
87. Wierzba-Bobrowicz T, Lewandowska E, Lechowicz W, Stepien T, Pasennik E. Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics. Folia Neuropathol 2005; 43: 81-89.
88. Busse S, Busse M, Schiltz K, Bielau H, Gos T, Brisch R, et al. Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease courserelated immune alterations?. Brain Behav Immun 2012; 26: 1273-1279.
89. Wierzba-Bobrowicz T, Lewandowska E, Kosno-Kruszewska E, Lechowicz W, Pasennik E, Schmidt-Sidor B. Degeneration of microglial cells in frontal and temporal lobes of chronic schizophrenics. Folia Neuropathol 2004; 42: 157-165.
90. Foster R, Kandanearatchi A, Beasley C, Williams B, Khan N, Fagerhol MK, et al. Calprotectin in microglia from frontal cortex is up-regulated in schizophrenia: evidence for an inflammatory process?. Eur J Neurosci 2006; 24: 3561-3566.
91. Steiner J, Mawrin C, Ziegeler A, Bielau H, Ullrich O, Bernstein HG, et al. Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol 2006; 112: 305-316.
92. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 2008; 42: 151-157.
93. Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E. Inflammationrelated genes up-regulated in schizophrenia brains. BMC Psychiatry 2007; 7: 46.
94. Schmitt A, Leonardi-Essmann F, Durrenberger PF, Parlapani E, Schneider-Axmann T, Spanagel R, et al. Regulation of immune-modulatory genes in left superior temporal cortex of schizophrenia patients: a genome-wide microarray study. World J Biol Psychiatry 2011; 12: 201-215.
95. Comte I, Kotagiri P, Szele FG. Regional differences in human ependymal and subventricular zone cytoarchitecture are unchanged in neuropsychiatric disease. Dev Neurosci 2012; 34: 299-309.
96. Nakatani N, Hattori E, Ohnishi T, Dean B, Iwayama Y, Matsumoto I, et al. Genomewide expression analysis detects eight genes with robust alterations specific to bipolar I disorder: relevance to neuronal network perturbation. Hum Mol Genet 2006; 15: 1949-1962.
97. Connor CM, Guo Y, Akbarian S. Cingulate white matter neurons in schizophrenia and bipolar disorder. Biol Psychiatry 2009; 66: 486-493.
98. Durrenberger PF, Fernando FS, Kashefi SN, Bonnert TP, Seilhean D, Nait-Oumesmar B, et al. Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study. J Neural Transm (Vienna) 2015; 122: 1055-1068.
99. Gos T, Myint AM, Schiltz K, Meyer-Lotz G, Dobrowolny H, Busse S, et al. Reduced microglial immunoreactivity for endogenous NMDA receptor agonist quinolinic acid in the hippocampus of schizophrenia patients. Brain Behav Immun 2014; 41: 59-64.
100. Kano S, Nwulia E, Niwa M, Chen Y, Sawa A, Cascella N. Altered MHC class I expression in dorsolateral prefrontal cortex of nonsmoker patients with schizophrenia. Neurosci Res 2011; 71: 289-293.
101. Sinkus ML, Adams CE, Logel J, Freedman R, Leonard S. Expression of immune genes on chromosome 6p21.3-22.1 in schizophrenia. Brain Behav Immunity 2013; 32: 51-62.
102. Stevens JR. Neuropathology of schizophrenia. Arch Gen Psychiatry 1982; 39: 1131-1139.
103. Bruton CJ, Crow TJ, Frith CD, Johnstone EC, Owens DG, Roberts GW. Schizophrenia and the brain: a prospective clinico-neuropathological study. Psychol Med 1990; 20: 285-304.
104. Falkai P, Bogerts B. Cell loss in the hippocampus of schizophrenics. Eur Arch Psychiatry Neurol Sci 1986; 236: 154-161.
105. Stark AK, Uylings HB, Sanz-Arigita E, Pakkenberg B. Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia. Am J Psychiatry 2004; 161: 882-888.
106. Brauch RA, Adnan El-Masri M, Parker JC Jr, El-Mallakh RS. Glial cell number and neuron/glial cell ratios in postmortem brains of bipolar individuals. J Affect Disord 2006; 91: 87-90.
107. Beasley CL, Honavar M, Everall IP, Cotter D. Two-dimensional assessment of cytoarchitecture in the superior temporal white matter in schizophrenia, major depressive disorder and bipolar disorder. Schizophr Res 2009; 115: 156-162.
108. Cotter D, Mackay D, Chana G, Beasley C, Landau S, Everall IP. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex 2002; 12: 386-394.
109. Cotter D, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 2001; 58: 545-553.
110. Benes FM, Davidson J, Bird ED. Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics. Arch Gen Psychiatry 1986; 43: 31-35.
111. Kurumaji A, Wakai T, Toru M. Decreases in peripheral-Type benzodiazepine receptors in postmortem brains of chronic schizophrenics. J Neural Transm (Vienna) 1997; 104: 1361-1370.
112. Bezchlibnyk YB, Sun X, Wang JF, MacQueen GM, McEwen BS, Young LT. Neuron somal size is decreased in the lateral amygdalar nucleus of subjects with bipolar disorder. J Psychiatry Neurosci 2007; 32: 203-210.
113. Selemon LD, Rajkowska G, Goldman-Rakic PS. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry 1995; 52: 805-818; discussion 819-820.
114. Selemon LD, Mrzljak J, Kleinman JE, Herman MM, Goldman-Rakic PS. Regional specificity in the neuropathologic substrates of schizophrenia: a morphometric analysis of Brocas area 44 and area 9. Arch Gen Psychiatry 2003; 60: 69-77.
115. Rajkowska G, Selemon LD, Goldman-Rakic PS. Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch Gen Psychiatry 1998; 55: 215-224.
116. Selemon LD, Rajkowska G, Goldman-Rakic PS. Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a threedimensional, stereologic counting method. J Comp Neurol 1998; 392: 402-412.
117. Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998; 95: 13290-13295.
118. Falkai P, Bogerts B, Rozumek M. Limbic pathology in schizophrenia: the entorhinal region-A morphometric study. Biol Psychiatry 1988; 24: 515-521.
119. Di Rosa E, Crow TJ, Walker MA, Black G, Chance SA. Reduced neuron density, enlarged minicolumn spacing and altered ageing effects in fusiform cortex in schizophrenia. Psychiatry Res 2009; 166: 102-115.
120. Cullen TJ, Walker MA, Eastwood SL, Esiri MM, Harrison PJ, Crow TJ. Anomalies of asymmetry of pyramidal cell density and structure in dorsolateral prefrontal cortex in schizophrenia. Br J Psychiatry 2006; 188: 26-31.
121. Chana G, Landau S, Everall I, Cotter D. Glial cell number and nuclear size in the mediodorsal thalamic nucleus (MDNT) in schizophrenia. Schizophr Res 2008; 102: 344-345.
122. Cotter D, Mackay D, Frangou S, Hudson L, Landau S. Cell density and cortical thickness in Heschls gyrus in schizophrenia, major depression and bipolar disorder. Br J Psychiatry 2004; 185: 258-259.
123. Benes FM, Vincent SL, Todtenkopf M. The density of pyramidal and nonpyramidal neurons in anterior cingulate cortex of schizophrenic and bipolar subjects. Biol Psychiatry 2001; 50: 395-406.
124. Chana G, Landau S, Beasley C, Everall IP, Cotter D. Two-dimensional assessment of cytoarchitecture in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia: evidence for decreased neuronal somal size and increased neuronal density. Biol Psychiatry 2003; 53: 1086-1098.
125. Benes FM, McSparren J, Bird ED, SanGiovanni JP, Vincent SL. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry 1991; 48: 996-1001.
126. Pennington K, Dicker P, Hudson L, Cotter DR. Evidence for reduced neuronal somal size within the insular cortex in schizophrenia, but not in affective disorders. Schizophr Res 2008; 106: 164-171.
127. Cotter D, Hudson L, Landau S. Evidence for orbitofrontal pathology in bipolar disorder and major depression, but not in schizophrenia. Bipolar Disord 2005; 7: 358-369.
128. Jonsson SA, Luts A, Guldberg-Kjaer N, Brun A. Hippocampal pyramidal cell disarray correlates negatively to cell number: implications for the pathogenesis of schizophrenia. Eur Arch Psychiatry Clin Neurosci 1997; 247: 120-127.
129. Beasley CL, Chana G, Honavar M, Landau S, Everall IP, Cotter D. Evidence for altered neuronal organisation within the planum temporale in major psychiatric disorders. Schizophr Res 2005; 73: 69-78.
130. Bogerts B, Hantsch J, Herzer M. A morphometric study of the dopaminecontaining cell groups in the mesencephalon of normals, Parkinson patients, and schizophrenics. Biol Psychiatry 1983; 18: 951-969.
131. Selemon LD, Begovic A. Stereologic analysis of the lateral geniculate nucleus of the thalamus in normal and schizophrenic subjects. Psychiatry Res 2007; 151: 1-10.
132. Hoistad M, Heinsen H, Wicinski B, Schmitz C, Hof PR. Stereological assessment of the dorsal anterior cingulate cortex in schizophrenia: absence of changes in neuronal and glial densities. Neuropathol Appl Neurobiol 2013; 39: 348-361.
133. Beckmann H, Lauer M. The human striatum in schizophrenia. II. Increased number of striatal neurons in schizophrenics. Psychiatry Res 1997; 68: 99-109.
134. Crow TJ, Ball J, Bloom SR, Brown R, Bruton CJ, Colter N, et al. Schizophrenia as an anomaly of development of cerebral asymmetry. A postmortem study and a proposal concerning the genetic basis of the disease. Arch Gen Psychiatry 1989; 46: 1145-1150.
135. Nasrallah HA, McCalley-Whitters M, Bigelow LB, Rauscher FP. A histological study of the corpus callosum in chronic schizophrenia. Psychiatry Res 1983; 8: 251-260.
136. Toyooka K, Watanabe Y, Iritani S, Shimizu E, lyo M, Nakamura R, et al. A decrease in interleukin-1 receptor antagonist expression in the prefrontal cortex of schizophrenic patients. Neurosci Res 2003; 46: 299-307.
137. Harris LW, Pietsch S, Cheng TM, Schwarz E, Guest PC, Bahn S. Comparison of peripheral and central schizophrenia biomarker profiles. PLoS ONE 2012; 7: e46368.
138. Dean B, Gibbons AS, Tawadros N, Brooks L, Everall IP, Scarr E. Different changes in cortical tumor necrosis factor-Alpha-related pathways in schizophrenia and mood disorders. Mol Psychiatry 2013; 18: 767-773.
139. Fillman SG, Sinclair D, Fung SJ, Webster MJ, Shannon Weickert C. Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder. Transl Psychiatry 2014; 4: e365.
140. Maida ME, Hurley SD, Daeschner JA, Moore AH, OBanion MK. Cytosolic prostaglandin E2 synthase (cPGES) expression is decreased in discrete cortical regions in psychiatric disease. Brain Res 2006; 1103: 164-172.
141. Tang B, Capitao C, Dean B, Thomas EA. Differential age- And disease-related effects on the expression of genes related to the arachidonic acid signaling pathway in schizophrenia. Psychiatry Res 2012; 196: 201-206.
142. Yokota O, Terada S, Ishihara T, Nakashima H, Kugo A, Ujike H, et al. Neuronal expression of cyclooxygenase-2, a pro-inflammatory protein, in the hippocampus of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 715-721.
143. Carletti R, Corsi M, Melotto S, Caberlotto L. Down-regulation of amygdala preprotachykinin A mRNA but not 3H-SP receptor binding sites in subjects affected by mood disorders and schizophrenia. Eur J Neurosci 2005; 21: 1712-1718.
144. Harrington KA, Augood SJ, Faull RL, McKenna PJ, Emson PC. Dopamine D1 receptor, D2 receptor, proenkephalin A and substance P gene expression in the caudate nucleus of control and schizophrenic tissue: a quantitative cellular in situ hybridisation study. Brain Res Mol Brain Res 1995; 33: 333-342.
145. Iadarola MJ, Ofri D, Kleinman JE. Enkephalin, dynorphin and substance P in postmortem substantia nigra from normals and schizophrenic patients. Life Sci 1991; 48: 1919-1930.
146. Kleinman JE, Hong J, Iadarola M, Govoni S, Gillin CJ. Neuropeptides in human brain-postmortem studies. Prog Neuropsychopharmacol Biol Psychiatry 1985; 9: 91-95.
147. Zech M, Bogerts B. Methionine-enkephalin and substance P in the basal ganglia of normals, Parkinson patients, Huntington patients, and schizophrenics. A qualitative immunohistochemical study. Acta Neuropathol 1985; 68: 32-38.
148. Toru M, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mitsushio H, et al. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 1988; 78: 121-137.
149. Roberts GW, Ferrier IN, Lee Y, Crow TJ, Johnstone EC, Owens DG, et al. Peptides, the limbic lobe and schizophrenia. Brain Res 1983; 288: 199-211.
150. Rioux L, Nissanov J, Joyce JN. Increased number of [125I] BH-substance p receptors in schizophrenia. Prog Neuro-psychopharmacol Biol Psychiatry 1998; 22: 1295-1299.
151. Burnet PW, Harrison PJ. Substance P (NK1) receptors in the cingulate cortex in unipolar and bipolar mood disorder and schizophrenia. Biol Psychiatry 2000; 47: 80-83.
152. Tooney PA, Crawter VC, Chahl LA. Increased tachykinin NK(1) receptor immunoreactivity in the prefrontal cortex in schizophrenia. Biol Psychiatry 2001; 49: 523-527.
153. Weidenhofer J, Yip J, Zavitsanou K, Huang XF, Chahl LA, Tooney PA. Immunohistochemical localisation of the NK1 receptor in the human amygdala: preliminary investigation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1313-1321.
154. Thomas AJ, Davis S, Ferrier IN, Kalaria RN, OBrien JT. Elevation of cell adhesion molecule immunoreactivity in the anterior cingulate cortex in bipolar disorder. Biol Psychiatry 2004; 55: 652-655.
155. Volk DW, Chitrapu A, Edelson JR, Roman KM, Moroco AE, Lewis DA. Molecular mechanisms and timing of cortical immune activation in schizophrenia. Am J Psychiatry 2015; 172: 1112-1121.
156. Sun Y, Zhang L, Johnston NL, Torrey EF, Yolken RH. Serial analysis of gene expression in the frontal cortex of patients with bipolar disorder. Br J Psychiatry Suppl 2001; 41: s137-s141.
157. Arion D, Unger T, Lewis DA, Levitt P, Mirnics K. Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry 2007; 62: 711-721.
158. Iwamoto K, Kakiuchi C, Bundo M, Ikeda K, Kato T. Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorders. Mol Psychiatry 2004; 9: 406-416.
159. Siegel BI, Sengupta EJ, Edelson JR, Lewis DA, Volk DW. Elevated viral restriction factor levels in cortical blood vessels in schizophrenia. Biol Psychiatry 2014; 76: 160-167.
160. Shao L, Vawter MP. Shared gene expression alterations in schizophrenia and bipolar disorder. Biol Psychiatry 2008; 64: 89-97.
161. Catts VS, Weickert CS. Gene expression analysis implicates a death receptor pathway in schizophrenia pathology. PLoS ONE 2012; 7: e35511.
162. Pandey GN, Rizavi HS, Ren X, Fareed J, Hoppensteadt DA, Roberts RC, et al. Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. J Psychiatr Res 2012; 46: 57-63.
163. Tonelli LH, Stiller J, Rujescu D, Giegling I, Schneider B, Maurer K, et al. Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatr Scand 2008; 117: 198-206.
164. Na KS, Jung HY, Kim YK. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2014; 48: 277-286.
165. Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 2006; 20: 532-545.
166. Ventriglio A, Gentile A, Stella E, Bellomo A. Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. Front Neurosci 2015; 9: 297.
167. Suvisaari J, Perala J, Saarni SI, Harkanen T, Pirkola S, Joukamaa M, et al. Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey. Eur Arch Psychiatry Clin Neurosci 2008; 258: 129-136.
168. Purkayastha S, Cai D. Neuroinflammatory basis of metabolic syndrome. Mol Metab 2013; 2: 356-363.
169. van Dijk G, van Heijningen S, Reijne AC, Nyakas C, van der Zee EA, Eisel UL. Integrative neurobiology of metabolic diseases, neuroinflammation, and neurodegeneration. Front Neurosci 2015; 9: 173.
170. Kalsheker NA. Alpha 1-Antichymotrypsin. Int J Biochem Cell Biol 1996; 28: 961-964.
171. Gopalan SM, Wilczynska KM, Konik BS, Bryan L, Kordula T. Astrocytespecific expression of the alpha1-Antichymotrypsin and glial fibrillary acidic protein genes requires activator protein-1. J Biol Chem 2006; 281: 1956-1963.
172. Kamboh MI, Minster RL, Kenney M, Ozturk A, Desai PP, Kammerer CM, et al. Alpha-1-Antichymotrypsin (ACT or SERPINA3) polymorphism may affect age-Atonset and disease duration of Alzheimers disease. Neurobiol Aging 2006; 27: 1435-1439.
173. Licastro F, Mallory M, Hansen LA, Masliah E. Increased levels of alpha-1-Antichymotrypsin in brains of patients with Alzheimers disease correlate with activated astrocytes and are affected by APOE 4 genotype. J Neuroimmunol 1998; 88: 105-110.
174. Ottervald J, Franzen B, Nilsson K, Andersson LI, Khademi M, Eriksson B, et al. Multiple sclerosis: identification and clinical evaluation of novel CSF biomarkers. J Proteomics 2010; 73: 1117-1132.
175. Zalli A, Jovanova O, Hoogendijk WJ, Tiemeier H, Carvalho LA. Low-grade inflammation predicts persistence of depressive symptoms. Psychopharmacology 2015.
176. Takao K, Kobayashi K, Hagihara H, Ohira K, Shoji H, Hattori S, et al. Deficiency of schnurri-2, an MHC enhancer binding protein, induces mild chronic inflammation in the brain and confers molecular, neuronal, and behavioral phenotypes related to schizophrenia. Neuropsychopharmacology 2013; 38: 1409-1425.
177. Bonow RH, Aid S, Zhang Y, Becker KG, Bosetti F. The brain expression of genes involved in inflammatory response, the ribosome, and learning and memory is altered by centrally injected lipopolysaccharide in mice. Pharmacogenomics J 2009; 9: 116-126.